JP2020522571A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020522571A5 JP2020522571A5 JP2020516959A JP2020516959A JP2020522571A5 JP 2020522571 A5 JP2020522571 A5 JP 2020522571A5 JP 2020516959 A JP2020516959 A JP 2020516959A JP 2020516959 A JP2020516959 A JP 2020516959A JP 2020522571 A5 JP2020522571 A5 JP 2020522571A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- patient
- day
- pharmaceutical composition
- administered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- BMAAMIIYNNPHAB-UHFFFAOYSA-N COc(cc1)c(COc(c(OC)c2)cc(N(C(c3c(C(O)=O)[s]cc3N3)=O)C3=O)c2F)c(F)c1F Chemical compound COc(cc1)c(COc(c(OC)c2)cc(N(C(c3c(C(O)=O)[s]cc3N3)=O)C3=O)c2F)c(F)c1F BMAAMIIYNNPHAB-UHFFFAOYSA-N 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023084336A JP7657855B2 (ja) | 2017-06-05 | 2023-05-23 | 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762515268P | 2017-06-05 | 2017-06-05 | |
| US62/515,268 | 2017-06-05 | ||
| PCT/EP2018/064768 WO2018224498A1 (en) | 2017-06-05 | 2018-06-05 | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023084336A Division JP7657855B2 (ja) | 2017-06-05 | 2023-05-23 | 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020522571A JP2020522571A (ja) | 2020-07-30 |
| JP2020522571A5 true JP2020522571A5 (enExample) | 2021-07-26 |
| JP7348171B2 JP7348171B2 (ja) | 2023-09-20 |
Family
ID=62620835
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020516959A Active JP7348171B2 (ja) | 2017-06-05 | 2018-06-05 | 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画 |
| JP2023084336A Active JP7657855B2 (ja) | 2017-06-05 | 2023-05-23 | 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023084336A Active JP7657855B2 (ja) | 2017-06-05 | 2023-05-23 | 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11980621B2 (enExample) |
| EP (1) | EP3634418A1 (enExample) |
| JP (2) | JP7348171B2 (enExample) |
| KR (2) | KR102839190B1 (enExample) |
| CN (1) | CN110996956A (enExample) |
| AU (2) | AU2018280742B2 (enExample) |
| CA (1) | CA3066190A1 (enExample) |
| EA (1) | EA201992612A1 (enExample) |
| MA (1) | MA49256A (enExample) |
| MX (1) | MX2019014483A (enExample) |
| SG (1) | SG11201911598WA (enExample) |
| WO (1) | WO2018224498A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202200254T1 (it) | 2016-09-30 | 2022-07-21 | Takeda Pharmaceuticals Co | Metodi di trattamento di fibromi uterini ed endometriosi |
| EP3634418A1 (en) | 2017-06-05 | 2020-04-15 | ObsEva S.A. | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| US11759464B2 (en) | 2017-06-05 | 2023-09-19 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| WO2020089190A2 (en) | 2018-10-29 | 2020-05-07 | ObsEva S.A. | Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosis |
| KR20220061120A (ko) * | 2019-08-08 | 2022-05-12 | 옵스에파 에스에이 | 에스트로겐-의존성 장애 치료용 조성물 및 방법 |
| CN113384581B (zh) * | 2020-03-12 | 2023-11-14 | 成都倍特药业股份有限公司 | 一种包含促性腺激素释放激素拮抗剂的药物组合物 |
| MX2022015003A (es) | 2020-05-29 | 2023-03-03 | Myovant Sciences Gmbh | Formas de dosificacion oral solidas de combinacion de antagonistas de la hormona liberadora de gonadotropina. |
| WO2022101303A1 (en) * | 2020-11-11 | 2022-05-19 | Myovant Sciences Gmbh | Methods of administering relugolix |
| WO2022179469A1 (zh) * | 2021-02-23 | 2022-09-01 | 南京明德新药研发有限公司 | 噻吩并嘧啶二酮类化合物及其应用 |
| CN115232144B (zh) * | 2021-04-22 | 2024-04-02 | 长春金赛药业有限责任公司 | 含氮稠环类衍生物、药物组合物及其制备方法和应用 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5342760A (en) | 1992-06-10 | 1994-08-30 | Abbott Laboratories | Determination of estradiol by competitive immunoassay |
| US5663054A (en) | 1995-03-03 | 1997-09-02 | Abbott Laboratories | Determination of steroids by competitive immunoassay |
| US7109171B2 (en) | 2000-02-28 | 2006-09-19 | Praecis Pharmaceuticals Inc. | Methods for treating FSH related conditions with GnRH antagonists |
| WO2002002533A1 (en) | 2000-07-05 | 2002-01-10 | Yamanouchi Pharmaceutical Co., Ltd. | Propane-1,3-dione derivatives |
| ZA200506611B (en) | 2003-01-29 | 2006-12-27 | Takeda Pharmaceutical | Thienopyrimidine compounds and use thereof |
| WO2005007165A1 (en) | 2003-07-07 | 2005-01-27 | Neurocrine Biosciences, Inc. | Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| EP1864976B1 (en) | 2005-03-31 | 2012-10-10 | Astellas Pharma Inc. | Propane-1,3-dion derivative or salt thereof |
| PT1939204E (pt) * | 2005-10-19 | 2013-03-14 | Kissei Pharmaceutical | Derivado heterocíclico fundido, composição medicinal contendo o mesmo, e sua utilização medicinal |
| US8765948B2 (en) | 2007-11-07 | 2014-07-01 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| EP2535342B1 (en) | 2010-02-10 | 2014-08-06 | Kissei Pharmaceutical Co., Ltd. | Salt of fused heterocyclic derivative and crystal thereof |
| CN104169287A (zh) | 2012-01-16 | 2014-11-26 | 拜耳知识产权有限责任公司 | 作为促性腺激素释放激素受体拮抗剂的螺二氢吲哚衍生物 |
| WO2013126517A1 (en) | 2012-02-21 | 2013-08-29 | Northwestern University | Anti-mullerian hormone detection in whole blood |
| KR20150048762A (ko) | 2012-09-07 | 2015-05-07 | 아스텔라스세이야쿠 가부시키가이샤 | 술포닐아미딘 화합물의 제조법 |
| JP6268093B2 (ja) | 2012-09-14 | 2018-01-24 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
| SMT202200255T1 (it) | 2012-09-28 | 2022-07-21 | Takeda Pharmaceuticals Co | Forma cristallina di 1-(4-1-(2,6-difluorobenzil)-5-dimetilamminometil-3-(6-metossipiridazin-3-il)-2,4-diosso-1,2,3,4-tetraidrotieno(2,3-d)-pirimidin-6il)fenil)-3-metossiurea |
| IL241595B2 (en) | 2013-03-15 | 2025-10-01 | Abbvie Inc | Composition for use in methods of treating heavy menstrual bleeding associated with uterine fibroids |
| AR095785A1 (es) | 2013-04-09 | 2015-11-11 | Bayer Pharma AG | Derivados de espiroindolina y composiciones farmacéutica de los mismos |
| CA3002791A1 (en) | 2015-09-01 | 2017-03-09 | Abbvie Inc. | Methods of administering elagolix |
| AU2017309015B2 (en) | 2016-08-08 | 2022-09-15 | Kissei Pharmaceutical Co., Ltd. | Administration and dosage of therapeutic agent for endometriosis |
| SMT202200254T1 (it) | 2016-09-30 | 2022-07-21 | Takeda Pharmaceuticals Co | Metodi di trattamento di fibromi uterini ed endometriosi |
| US11759464B2 (en) | 2017-06-05 | 2023-09-19 | Kissei Pharmaceutical Co., Ltd. | Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss |
| EP3634418A1 (en) | 2017-06-05 | 2020-04-15 | ObsEva S.A. | Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis |
| KR20210100623A (ko) | 2018-11-07 | 2021-08-17 | 옵스에파 에스에이 | 에스트로겐-의존성 장애의 치료를 위한 조성물 및 방법 |
-
2018
- 2018-06-05 EP EP18731378.8A patent/EP3634418A1/en active Pending
- 2018-06-05 US US16/619,776 patent/US11980621B2/en active Active
- 2018-06-05 CA CA3066190A patent/CA3066190A1/en active Pending
- 2018-06-05 AU AU2018280742A patent/AU2018280742B2/en active Active
- 2018-06-05 MX MX2019014483A patent/MX2019014483A/es unknown
- 2018-06-05 KR KR1020197038977A patent/KR102839190B1/ko active Active
- 2018-06-05 CN CN201880050650.3A patent/CN110996956A/zh active Pending
- 2018-06-05 EA EA201992612A patent/EA201992612A1/ru unknown
- 2018-06-05 JP JP2020516959A patent/JP7348171B2/ja active Active
- 2018-06-05 KR KR1020257024754A patent/KR20250117836A/ko active Pending
- 2018-06-05 SG SG11201911598WA patent/SG11201911598WA/en unknown
- 2018-06-05 MA MA049256A patent/MA49256A/fr unknown
- 2018-06-05 WO PCT/EP2018/064768 patent/WO2018224498A1/en not_active Ceased
-
2023
- 2023-05-23 JP JP2023084336A patent/JP7657855B2/ja active Active
-
2024
- 2024-03-14 AU AU2024201701A patent/AU2024201701B2/en active Active
- 2024-04-12 US US18/634,241 patent/US20240293414A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020522571A5 (enExample) | ||
| TWI314053B (en) | Use of compounds that are effective as selective opiate receptor modulators | |
| KR20240099142A (ko) | 병용 요법 | |
| JP2023113715A (ja) | 子宮内膜症の治療のためのゴナドトロピン放出ホルモンアンタゴニスト投与計画 | |
| JP2020522525A5 (enExample) | ||
| AU2009238379A1 (en) | Folic acid-containing pharmaceutical compositions, and related methods and delivery systems | |
| US20230018765A1 (en) | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof | |
| CA2746787A1 (en) | Method of increasing testosterone and related steroid concentrations in women | |
| NO334991B1 (no) | Blandinger for å øke testosteron og beslektede konsentrasjoner av steroid hos kvinner | |
| EP0747054B1 (en) | Methods for minimizing bone loss | |
| US20040067918A1 (en) | Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative | |
| JP2003509467A5 (enExample) | ||
| JP2005526022A5 (ja) | 関節リウマチの処置 | |
| JP2024529777A (ja) | ＡＲＮｉとカルシウムイオンアンタゴニストとの医薬組成物および応用 | |
| CN102421450B (zh) | 治疗虚弱的方法 | |
| TWI835716B (zh) | 治療良性前列腺增殖徵候與症狀之四氫環戊[b]吲哚化合物與磷酸二酯酶抑制劑 | |
| MXPA04009039A (es) | Combinacion de un antagonista de los receptores de la aldosterona y un agente secuestrante de los acidos biliares. | |
| JP2006306872A (ja) | 選択的エストロゲン受容体修飾因子及びアロマターゼ阻害剤の組み合わせよりなる医薬組成物及び方法 | |
| AU2005269052A1 (en) | Combination comprising a BCRP inhibitor and 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide | |
| JP2019524846A (ja) | 子宮内膜症の治療のための投与レジメン | |
| AU2016370297A1 (en) | Combination therapy for cancer | |
| JP2026500731A (ja) | 医薬組合せおよび医薬組成物、ならびにその使用方法 | |
| Agrawal et al. | Topical Nitroglycerin: A New and Safe Treatment Option for Osteoporosis | |
| Agarwal et al. | Topical Nitroglycerin for Osteoporosis: Old Drug New Application | |
| JP2005531622A5 (enExample) |